Found 3 clinical trials

SPROUT - Pediatric Psoriasis - CC-10004 PPSO 003 - Canada
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque
- 0 views
- 05 Sep, 2022
Have been diagnosed with moderate to severe Ulcerative Colitis?
Have been diagnosed with moderate to severe Ulcerative Colitis?
- 72 views
- 08 Nov, 2020
- 1 location
A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
This study was created to provide subjects who complete Week 52 (end of Apremilast Extension Phase) of study CC-10004-PPSO-003 the option to continue to receive open-label apremilast therapy
- 0 views
- 14 Oct, 2022
- 48 locations